Skip to main content

ORIGINAL RESEARCH article

Front. Immunol.
Sec. Nutritional Immunology
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1425119
This article is part of the Research Topic Vitamin D: From Pathophysiology to Clinical Impact Volume II View all 16 articles

Implications of vitamin D levels or status for mortality in rheumatoid arthritis: analysis of 2001-2018 data from the National Health and Nutrition Examination Survey

Provisionally accepted
Yalin Feng Yalin Feng 1Ping Zhu Ping Zhu 2Yan d. Dan Yan d. Dan 3Xu Wang Xu Wang 3Caiyun Chen Caiyun Chen 1Zhongyuan Zhang Zhongyuan Zhang 3Yian Tian Yian Tian 3Jiajia Wang Jiajia Wang 3Shanshan Liu Shanshan Liu 3Ju Li Ju Li 3Deqian Meng Deqian Meng 3Kai Wang Kai Wang 4*
  • 1 Department of Medical Laboratory, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huaian, China
  • 2 Department of Endocrinology, The affiliated Huaian Hospital of Jiangsu College Of Nursing & Huaian Cancer Hospital, Huaian, China
  • 3 Department of Rheumatology and Immunology, The affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, China
  • 4 Department of Rheumatology, The affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, China

The final, formatted version of the article will be published soon.

    Background: Inadequate levels of vitamin D (VitD) have been linked to increased rates of various health conditions and mortality. However, little is known about the relationship between mortality outcomes and 25-hydroxyvitamin D [25(OH)D] levels in individuals with rheumatoid arthritis (RA). This study aimed to examine this association using data from the National Health and Nutrition Examination Survey. Methods: A cohort of 2,290 individuals aged 20 to 85 years with RA was analyzed. Lower 25(OH)D levels were inversely associated with all-cause mortality, with a hazard ratio (HR) of 0.91 (0.87 to 0.96) per 10 nmol/L increase. Comparatively, the HR for the VitD insufficiency group was 0.64 (0.50 to 0.83), and for the VitD sufficiency group, it was 0.60 (0.44 to 0.80), both compared to the VitD deficiency group. Cause-specific analysis showed that higher 25(OH)D levels were associated with reduced mortality from heart disease (HR: 0.88, 0.82 to 0.95) and malignant neoplasms (HR: 0.86, 0.79 to 0.94). No significant correlation was found between 25(OH)D levels and cause-specific mortalities for other conditions. Results: Stratified by gender, the HR for males was 0.92 (0.85 to 0.99) and for females was 0.91 (0.86 to 0.98) per 10 nmol/L increase in 25(OH)D levels. Among individuals aged 20-59 years, no significant correlation was observed, while for those aged 60 years and older, the HR was 0.86 (0.82 to 0.90) per 10 nmol/L increase. Nonlinear analysis identified a sharp increase in HR below 59.95 nmol/L, while HR remained below 1 for 25(OH)D levels above 59.95 nmol/L. Conclusion: This study reveals a strong negative correlation between 25(OH)D levels and overall mortality in individuals with RA. Notably, this association is particularly significant for mortality related to heart disease and malignant neoplasms. Targeted VitD supplementation should be emphasized, especially in individuals aged 60 years and older with RA. The proposed minimum threshold for adequate 25(OH)D levels in the RA population is 60 nmol/L.

    Keywords: Vitamin D, Vitamin D levels, Vitamin D status, Mortality, Rheumatoid arthritis

    Received: 29 Apr 2024; Accepted: 23 Sep 2024.

    Copyright: © 2024 Feng, Zhu, Dan, Wang, Chen, Zhang, Tian, Wang, Liu, Li, Meng and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Kai Wang, Department of Rheumatology, The affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.